Monopar Therapeutics Files 8-K

TL;DR

Monopar dropped an 8-K, likely standard disclosures. Keep an eye out for details.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on December 6, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. Specific details regarding material events or financial performance are not elaborated upon in the provided text, but the filing indicates a standard disclosure process.

Why It Matters

This 8-K filing indicates that Monopar Therapeutics is making required disclosures to the SEC, which is standard practice for publicly traded companies to keep investors informed.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative events.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• December 6, 2024 (date) — Date of earliest event reported
• 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
• 847-388-0349 (phone_number) — Registrant's telephone number

FAQ

From the Filing

0001437749-24-036825.txt : 20241206 0001437749-24-036825.hdr.sgml : 20241206 20241206080022 ACCESSION NUMBER: 0001437749-24-036825 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241206 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241206 DATE AS OF CHANGE: 20241206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241530563 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20241205_8k.htm FORM 8-K mnpr20241205_8k.htm false 0001645469 0001645469 2024-12-06 2024-12-06     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 6, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On December 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that a first patient was dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated December 5, 2024 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)         SIGNATURE   Pursua